Hantavirus vaccine in 2026?
As of 14:05 UTC on 2 Nov 2026, Polymarket prices “Hantavirus vaccine in 2026?” at 3%. The market has $444 in Polymarket-reported 24-hour volume. pdata.world compares it with 21 related events on Polymarket, Manifold and Kalshi.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
